Jerini AG reaches milestones in two research alliances with Baxter Healthcare
Although financial terms were not disclosed, one agreement provides for an upfront payment, FTE funding and milestones as well as performance payments for Jerini on the commercial sale of products. Under the second agreement Jerini receives FTE funding and is eligible for future success-based milestone and royalty payments.
"Jerini's Peptides-To-Drugs platform is a perfect fit to Baxter's long-term therapeutic aspirations", said Jens Schneider-Mergener, Chief Executive Officer of Jerini. "We are delighted by the validation our technology receives through the further extension of the agreement with Baxter".
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.